OB/GYN Clinical Alert
RSSArticles
-
OTC Antifungal Drug Misuse Associated With Patient-Diagnosed Vulvovaginal Candidiasis
-
Evaluation of a Consumer-Oriented Internet Health Care Report Card
-
Postmenopausal Hormone Therapy and the Risk of Breast Cancer
-
Pharmacology Watch: GlaxoSmithKline Withdraws Lymerix: Company ‘Cuts Losses’ on Controversial Lyme Disease Vaccine
-
MORE Data, MORE Questions
-
Intraperitoneal Chemotherapy for Ovarian Carcinoma
-
Empiric Vaginal Metronidazole in the Management of the ASCUS Pap Smear
-
Reduced Fetal Movement, Uterine Arteries, and Stillbirth
A recent study has shown a link between abnormal uterine artery waveforms in the second trimester and reduced fetal movements later in pregnancy, as well as with stillbirth and small for gestational age. -
More Promise from Olaparib in Recurrent Ovarian Cancer: The BRCA Cohort
Olaparib, a poly (ADP)-ribose polymerase (PARP) inhibitor, demonstrated substantial delay until progression when administered to women as a maintenance therapy with BRCA-mutant recurrent ovarian cancer. -
AMH: Marker of Ovarian Reserve and More
Serum anti-Mullerian hormone (AMH) has been well-established as an accurate marker of ovarian reserve. It is solely produced in the human ovary by the granulosa cells.